NCT06522256 Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial
| NCT ID | NCT06522256 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Condition | HPV Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-03-20 |
| Primary Completion | 2027-07-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.
Eligibility Criteria
Inclusion Criteria: * Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study; * Informed and written signed consent * Participant with regular health insurance Exclusion Criteria: * Participant under guardianship or curatorship * Participant with free State medical assistance * Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.